VTE Risk in Pregnancy

Assess VTE risk during pregnancy and postpartum using RCOG-based scoring. Evaluate pre-existing, obstetric, and transient risk factors to guide prophylaxis decisions. Free online tool.

About This Calculator

The VTE Risk Score in Pregnancy Calculator helps healthcare professionals and patients assess the risk of venous thromboembolism (VTE) during pregnancy and the postpartum period. Based on the Royal College of Obstetricians and Gynaecologists (RCOG) green-top guideline (GTG No. 37a), this tool evaluates 28 risk factors across three categories — pre-existing, obstetric, and transient — assigning weighted scores of 1-4 points to each factor.

The calculator automatically computes BMI from height and weight. Age over 35 is scored automatically. The total score determines the risk category: Low Risk (0-1 points), Intermediate Risk (2-3 points), or High Risk (4+ points or any single factor worth 3-4 points). High-risk patients should be considered for pharmacological prophylaxis with low molecular weight heparin (LMWH) throughout pregnancy and for 6 weeks postpartum.

VTE is 4-10 times more common in pregnant women compared to non-pregnant women of the same age, and it remains a leading cause of maternal mortality in the UK, US, and other developed nations. The RCOG recommends systematic VTE risk assessment at the first antenatal visit (booking), at delivery, and whenever clinical circumstances change.

Regional Guidelines

United Kingdom: The RCOG guideline (GTG No. 37a) is the standard for VTE risk assessment in pregnancy. The NHS recommends LMWH (tinzaparin or enoxaparin) for antenatal and postnatal prophylaxis. Risk assessment should be performed at booking, at every hospital admission, and after delivery.

United States: ACOG (American College of Obstetricians and Gynecologists) recommends thromboprophylaxis based on similar risk stratification. The ACOG practice bulletin on thromboembolism in pregnancy provides comparable guidance with LMWH as the preferred agent.

India: The FOGSI (Federation of Obstetric and Gynaecological Societies of India) guidelines align with RCOG/ACOG recommendations. LMWH prophylaxis is recommended for high-risk women, with dose adjustments based on weight and renal function. Cost and availability may influence choice of agent.

Frequently Asked Questions

What is VTE in pregnancy?

VTE (Venous Thromboembolism) in pregnancy refers to blood clot formation in veins that occurs during pregnancy or the postpartum period. Pregnant women are 4-10 times more likely to develop VTE than non-pregnant women of the same age due to hormonal changes, venous stasis from the growing uterus, and hypercoagulability. VTE is a leading cause of maternal death in developed countries.

How does the VTE risk score calculator in pregnancy work?

Our VTE risk calculator in pregnancy uses the Royal College of Obstetricians and Gynaecologists (RCOG) risk factor scoring system. It evaluates three categories of risk factors: pre-existing (age, BMI, previous VTE, thrombophilia, comorbidities), obstetric (pre-eclampsia, multiple pregnancy, cesarean section, PPH), and transient (surgery, hyperemesis, infection). Each factor carries a score of 1-4 points, and the total score determines low (0-1), intermediate (2-3), or high risk (4+).

What is considered a high VTE risk score in pregnancy?

A total score of 4 or more points, or the presence of any single risk factor worth 3-4 points, indicates high VTE risk in pregnancy. High-risk patients should be considered for pharmacological prophylaxis with low molecular weight heparin (LMWH) during pregnancy and for 6 weeks postpartum. Risk factors worth 4 points include previous VTE (excluding major surgery-related) and OHSS in the first trimester.

What are the RCOG recommendations for VTE prophylaxis in pregnancy?

The RCOG guidelines recommend LMWH as the agent of choice for antenatal and postnatal VTE prophylaxis. High-risk women (score 4+) should receive pharmacological prophylaxis throughout pregnancy and for 6 weeks postpartum. Intermediate-risk women (score 2-3) should be considered for prophylaxis based on clinical judgment. Low-risk women (score 0-1) should be encouraged to mobilize and stay hydrated. Mechanical methods like compression stockings can supplement pharmacological prophylaxis.

Is VTE risk higher during pregnancy or after delivery?

VTE risk is highest in the postpartum period, particularly in the first 6 weeks after delivery. The risk during pregnancy increases progressively from the first trimester and peaks around delivery. Factors like cesarean section, postpartum hemorrhage, and prolonged labor further elevate postpartum risk. The RCOG risk assessment should be performed at booking and re-evaluated after delivery or if clinical circumstances change.

Can VTE in pregnancy be prevented?

Yes, VTE in pregnancy can be effectively prevented with appropriate prophylaxis. Pharmacological prevention with LMWH is safe and effective, and can be used throughout pregnancy and breastfeeding. Mechanical prevention includes compression stockings, early ambulation after delivery, and pneumatic compression devices during cesarean section. Proper hydration and leg exercises also help reduce risk. The key is identifying at-risk women through systematic risk assessment.

What are the symptoms of VTE in pregnancy?

Deep vein thrombosis (DVT) symptoms include unilateral leg swelling, pain, warmth, and redness, typically in the left leg. Pulmonary embolism (PE) symptoms include sudden shortness of breath, chest pain (especially on deep breathing), coughing up blood, and rapid heart rate. Cerebral venous sinus thrombosis (CVST) presents with severe headache, seizures, and neurological deficits. Anyone with these symptoms during pregnancy or postpartum should seek emergency medical attention.

How does BMI affect VTE risk in pregnancy?

Obesity significantly increases VTE risk in pregnancy. A BMI of 30-39.9 adds 1 point to the RCOG risk score, while a BMI of 40 or more adds 2 points. Obesity contributes to venous stasis, reduced mobility, and a pro-inflammatory state that promotes coagulation. Weight management before pregnancy and appropriate risk-based prophylaxis can help mitigate this risk.